Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Sherko Kümmel,1 Christian Jackisch,2 Volkmar Müller,3 Andreas Schneeweiss,4 Sandra Klawitter,5 Michael P Lux6 1Breast Unit Essen, Kliniken Essen-Mitte, Essen, Germany; 2Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany; 3Department of Gynecology, University Medic...

Full description

Bibliographic Details
Main Authors: Kümmel S, Jackisch C, Müller V, Schneeweiss A, Klawitter S, Lux MP
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:Cancer Management and Research
Subjects:
progression-free survival
overall survival
endpoint
metastatic breast cancer
clinical trial
regulatory authorities
Online Access:https://www.dovepress.com/can-contemporary-trials-of-chemotherapy-for-her2-negative-metastatic-b-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/can-contemporary-trials-of-chemotherapy-for-her2-negative-metastatic-b-peer-reviewed-article-CMAR

Similar Items